Beyond Neoantigens: Alternative Sources of Antigens for Personalized Cancer Immunotherapy

Time: 12:00 pm
day: Pre-Conference Focus Day


  • Neoantigen vaccines are primarily being tested in patients with high mutational burden cancers such as melanoma and NSCLC
  • Patients with lower mutational burden cancers are less likely to have good, targetable neoantigens
  • Looking beyond neoantigens has the potential to make personalized cancer vaccines relevant for more patients